Abstract 519P
Background
The phase Ⅲ CASPIAN study established durvalumab (D) plus etoposide with cisplatin or carboplatin (EP) as first-line standard of care (1L SoC) of ES-SCLC. The multicenter, single-arm, phase Ⅲb ORIENTAL study evaluated 1L D+EP in a large, real-world-like patient (pt) cohort in China. Preliminary safety and efficacy results were consistent with CASPIAN. Here we report final results and subgroup analysis.
Methods
Treatment-naïve ES-SCLC pts ≥18 years old with ECOG PS 0–2 received D 1500 mg + EP intravenously every 3 weeks for 4–6 cycles, followed by D monotherapy every 4 weeks until progressive disease or intolerable toxicity. Primary endpoints were immune-mediated adverse events (imAEs) and grade ≥3 AEs. Secondary endpoints included OS, PFS, and tumor response.
Results
166 pts from 32 sites were enrolled by Aug 2021 and 165 received study treatment (median [m] age 65 years; 140 [84.8%] male). At baseline, 6 (3.6%) were ECOG PS 2, 155 (93.9%) were stage Ⅳ, 21 (12.7%) had brain metastases, and 44 (26.7%) had liver metastases. By data cut-off (31 Mar 2023), median cycle number of D was 7 (range 1–25). 92 (55.8%) started subsequent systemic anticancer therapy. 40 (24.2%) reported imAEs (most common [≥5%]: hyperthyroidism [6.1%] and hypothyroidism [6.1%]; grade 1/2 mostly). Grade ≥3 AEs occurred in 82 (49.7%) pts and led to treatment interruption in 24 (14.5%). mOS was 14.8 months (mo) (m follow-up [mFU] 20.5 mo). 118 (71.5%) pts received D maintenance, with mOS of 16.6 mo. 85 (51.5%) pts received >4 EP cycles, with mOS of 17.4 mo (Table). mPFS was 6.3 mo (mFU 8.6 mo). ORR was 76.4%, with 3 (1.8%) complete responses (RECIST 1.1). Table: 519P
N=165 | 95% CI | ||
Any-cause AEs, n (%) | 161 (97.6) | ||
Grade ≥3 AEs, n (%) | 82 (49.7) | ||
imAEs, n (%) | 40 (24.2) | ||
Grade ≥3 imAEs, n (%) | 11 (6.7) | ||
mOS, mo | 14.8 | 13.2–16.0 | |
12-mo OS, % | 60.8 | 52.8–67.9 | |
24-mo OS, % | 26.2 | 17.5–35.6 | |
mPFS, mo | 6.3 | 5.6–6.5 | |
12-mo PFS, % | 17.6 | 12.0–24.1 | |
ORR, % | 76.4 | 69.1–82.6 | |
DCR, % | 89.1 | 83.3–93.4 | |
mDoR, mo | 5.1 | 4.7–5.7 | |
Subgroup analysis | n | mOS, mo | 95% CI |
Received D maintenance | 118 | 16.6 | 15.1–18.8 |
ECOG PS | |||
0–1 | 159 | 15.1 | 13.3–16.1 |
2 | 6 | 9.2 | 6.4–Not Available |
Number of EP cycles | |||
≤4 | 80 | 12.7 | 9.4–15.1 |
>4 | 85 | 17.4 | 14.0–21.7 |
First-line platinum | |||
Cisplatin | 17 | 11.1 | 6.5–18.8 |
Carboplatin | 148 | 15.2 | 13.3–16.6 |
Brain metastases | |||
With | 21 | 11.1 | 8.5–14.3 |
Without | 144 | 15.3 | 13.3–17.4 |
Liver metastases | |||
With | 44 | 9.6 | 6.5–13.2 |
Without | 121 | 16.1 | 14.3–18.2 |
Conclusions
Final results of ORIENTAL showed in the largest to date, real-world-like Chinese ES-SCLC cohort that D+EP was effective and well tolerated, further supporting D+EP as 1L SoC in China.
Clinical trial identification
NCT04449861.
Editorial acknowledgement
Medical writing support for the development of the abstract, under the input and direction of the authors, was provided by Xiaowei Ning and Bo Lyu from Costello Medical Singapore and funded by AstraZeneca China.
Legal entity responsible for the study
AstraZeneca China.
Funding
AstraZeneca China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
26P - Subcutaneous trastuzumab versus intravenous trastuzumab for treatment of patients with HER2-positive breast cancer: A time, motion and cost-benefit assessment in a day care oncology unit in China
Presenter: Bei Sun
Session: Poster Display
Resources:
Abstract
27P - The biological characteristics of HER2-low in TNBC using mRNA profiling and molecular subtypes
Presenter: Asako Tsuruga
Session: Poster Display
Resources:
Abstract
28P - One-week ultra-hypofractionated partial breast RT in early breast cancer: 3DCRT vs IMRT
Presenter: Nurilla Zaynutdinov
Session: Poster Display
Resources:
Abstract
30P - Stereotactic body radiotherapy using cyberknife versus interstitial brachytherapy in accelerated partial breast irradiation on left-sided breast: A comparison of preliminary clinical result and dosimetric characteristics
Presenter: Ting-Na Wei
Session: Poster Display
Resources:
Abstract
31P - Prognostic implication of breast edema on preoperative breast MRI in breast cancer
Presenter: Ki-tae Hwang
Session: Poster Display
Resources:
Abstract
32P - Efficacy of olanzapine in the prophylaxis of delayed chemotherapy-induced nausea and vomiting in breast cancer patients receiving dose-dense AC with a steroid-sparing regimen: A single-center pilot study
Presenter: Manami Tada
Session: Poster Display
Resources:
Abstract
34P - Social support as the mediator of the association between unmet needs and happiness among women with early breast cancer
Presenter: Nithiya Sinarajoo
Session: Poster Display
Resources:
Abstract
35P - Prospective study assessing the efficacy and safety of a scalp cooling device for the prevention of alopecia in breast cancer patients undergoing (neo)adjuvant chemotherapy
Presenter: Winnie Yeo
Session: Poster Display
Resources:
Abstract
37P - To excise or not to excise: Preventive management of early breast cancer in atypical ductal hyperplasia patients
Presenter: Clarisse Hing
Session: Poster Display
Resources:
Abstract
38P - Exploring prognostic factors in patients achieving PCR after neoadjuvant therapy for triple-negative breast cancer: A retrospective study based on SEER data
Presenter: Lv Wenjie
Session: Poster Display
Resources:
Abstract